GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vonafexor   Click here for help

GtoPdb Ligand ID: 13935

Synonyms: EYP-001 | EYP001 | PLX-007 | PLX007
Compound class: Synthetic organic
Comment: Vonafexor (EYP001) is an oral farnesoid X receptor (NR1H4) agonist [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 95.53
Molecular weight 489.76
XLogP 2.55
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C(=C1)Cl)S(=O)(=O)N2CCN(CC2)C3=CC=C4C(=C3Cl)C=C(C(=O)O)O4)Cl
Isomeric SMILES C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl
InChI InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
InChI Key XLGQSYUNOIJBNR-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, Laveille C, Radreau-Pierini P, Darteil R, Vonderscher J et al.. (2021)
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study.
J Viral Hepat, 28 (12): 1690-1698. [PMID:34467593]
2. Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E. (2020)
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Expert Opin Investig Drugs, 29 (6): 623-632. [PMID:32552182]
3. Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R et al.. (2023)
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
J Hepatol, 78 (3): 479-492. [PMID:36334688]
4. Tang Y, Fan Y, Wang Y, Wang D, Huang Q, Chen T, Cao X, Wen C, Shen X, Li J et al.. (2024)
A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
Biomed Pharmacother, 175: 116658. [PMID:38701562]